

The fields of interest of the attending 10 global pharma companies

Please read carefully what the attending global pharmaceutical companies are looking for, to identify how they could benefit from the products, services and innovations your organization has to offer.

Global Pharma Partners

AbbVie	2
Biogen	3
Janssen, Pharmaceutical Companies of Johnson & Johnson	4
Merck (KGaA)	7
MSD	8
Novartis Neuroscience	9
Orion	12
Roche	13
Sanofi Genzyme	14
Takeda	15

AbbVie

Our commitment to preserving the personhood of those living with neurological and psychiatric disorders is unwavering. AbbVie Neuroscience portfolio consists of approved therapies and a robust pipeline in neurological and psychiatric disorders with high unmet need.

Our areas of interest include:

- Disease modification approaches for neurodegenerative diseases, including Alzheimer's and Parkinson's disease, and select diseases driven by shared biological pathways
- Psychiatric diseases, including bipolar disorder, bipolar depression, major depressive disorder, generalized anxiety disorder and schizophrenia
- Symptomatic approaches with clinical validation for cognitive and neurobehavioral deficits in Alzheimer's and Parkinson's disease
- Migraine
- Spasticity and movement disorders; neurorestoration in multiple sclerosis

Biogen

The interest areas of Biogen include:

- Multiple sclerosis
- Spinal muscular atrophy
- Neuroimmunology
- Alzheimer's disease and dementia
- Neuromuscular disorders
- Movement disorders
- Ophthalmology
- Immunology
- Neurocognitive disorders
- Acute neurology
- Pain

Janssen, Pharmaceutical Companies of Johnson & Johnson

Neurodegenerative Disorders: Alzheimer's disease, Parkinson's disease, MS

Disease Areas & Solutions

Disease modifying activity

Agents in preclinical stage or later should have preclinical validated in-vivo, test-of-concept data.

- Tau modulators
- Modulators of α -synuclein spread and clearance
- Compounds that promote synaptic resilience
- Modulators of ApoE4 pathology
- Neuroimmune pathways
- Therapeutic targets driven by human genetics
- New treatment modalities for neurodegenerative diseases –gene therapy, ASOs
- Validated mechanisms that slow or halt the progression of MS (preferably with clinical evidence)

Platforms & Therapeutics

Symptomatic treatments of cognitive impairment and neuropsychiatric conditions

- Novel agents with Phase 2 proof-of-concept in neuropsychiatric symptoms or neuropsychiatric symptoms with cognitive impairment that exhibit superior efficacy to standard of care (e.g., superior to antipsychotics, acetylcholinesterase inhibitors) as monotherapy or adjunctive therapy with synergistic efficacy.

Biomarkers and Diagnostics

- Prognostic, diagnostic and disease progression biomarkers
- Diagnostic imaging agents, including imaging of disease pathology, structural and functional MRI
- Improved CSF and blood biomarker assays

Psychiatry-Mood Disorders & Schizophrenia

Disease Areas & Solutions

Depression and Treatment Resistant Depression

- Novel therapeutic agents that have fast onset of action, good safety and tolerability profiles, and that address common co-morbidities (e.g., anxiety, insomnia and substance abuse).
 - Glutamatergic modulators
 - Neuroactive cytokines
 - Molecules that positively impact synaptic plasticity and cellular resilience
- Phase 2 and later stage opportunities with defined mechanisms of action and superior efficacy over standard of care.

Bipolar Depression

- Novel therapeutic agents that provide rapid improvement in bipolar depression and in suicidal patients and that produce long-term stabilization of mood and prevent recurrences.

Schizophrenia

- Novel therapies in Phase 2b or later to address the poorly treated symptom domains of schizophrenia, with special emphasis on treatment of cognitive impairment and negative symptoms
 - Prognostic biomarkers to identify patients at risk for disease
 - Predictive biomarkers for treatment response
 - Integrated solutions for patient diagnosis or treatment assessment
 - Cognitive tests for measuring disease progression

Glutamatergic Pathway Area

Enabling Capabilities/Glutamatergic Assets/Development Partnership:

Capabilities, platforms and expertise

- Biomarkers of glutamatergic signalling and dysbiosis
- Diagnostic biomarkers to identify/stratify responders to drugs acting within the glutamatergic pathway across neurologic and neuropsychiatric disease states
- Data science to identify novel targets indications for glutamatergic drugs
- Clinical development

Collaboration opportunities for clinical-staged assets acting within the glutamatergic pathway to treat conditions with high unmet medical need

- PTSD
- Epilepsies
- Chronic pain
- Prodromal psychoses/CHR

Co-funding and risk-sharing partnerships to advance the portfolio

Merck (KGaA)

Biomarkers:

- In MS and other autoimmunity diseases
- Related to prognostic and predictive measures (e.g. treatment efficacy)

Methodologies:

- State of the art technologies in imaging and diagnostics
- Innovations (within methods, diagnostic, patient support etc.)

Clinical biobank and registry studies supporting analytical methods.

For more information of our pipeline at:

<https://www.merckgroup.com/en/research/healthcare-pipeline.html>

MSD

The interest areas of MSD include:

- Pre-/nonclinical research models (e.g in vivo PET imaging)
- Neuroimaging
- Neuroinflammation
- Chronic, neuropathic pain
- Neurodegenerative diseases
- Schizophrenia
- Registries and biobanks

Novartis Neuroscience

Indications & Concepts

Targets with validated data in humans (genetic –large databases/ pharmacological/ clinical/ medical records). Disease modifying treatment. First-in-class/best-in-class programs.

Neurodegeneration

Alzheimer's Disease, Parkinson's Disease, Huntington Disease, ALS and related Tauopathies, Synucleinopathies and TDP43-opathies

- Targets must have human genetic or human pharmacological validation; with particular interest in targets involved in endosomal/lysosomal function or mitochondrial QC
- Neuroinflammation: Microglial, astrocyte and vascular targets
- Preclinical assays including systems using stem cell and mouse models
- Novel technologies and approaches to known, well validated targets

Neuropsychiatric disorders

Schizophrenia, Depression, Bipolar Disorder, Anxiety, Autism, Fatigue

- Targets must have human genetic or human pharmacological validation
- Novel targets for prevention and disease modification
- Novel assays and technologies
- Immunopsychiatry: Novel immune targets and assays
- Novel strategies for modulating the activity of brain regions and cell types that could have a transformative effect on symptoms

Pediatric neurology

Autism, Anxiety, Learning Disabilities, Intellectual Disability, Pediatric Epilepsy, Rare and orphan diseases

- must have human genetic or human pharmacological validation

- Gene therapy program for indications affecting more than 5000 patients per year worldwide
- Natural history studies

Multiple Sclerosis

- Remyelinating therapies
- Therapies promoting Immune tolerance

Neuroinflammation

- In neurodegeneration and psychiatric disorders
- Neuroinflammation and microbiome (Novel mechanisms of action)

Enabling Technologies

- Biomarkers for the diseases indicated above: Diagnostic and prognostic markers. Novel clinical endpoints and digital endpoints.
- New AAV capsids and other viral vectors targeting nervous system cells with:
 - improved transduction and targeting
 - increased payload size
 - reduced immunogenicity and toxicity
 - cell-specific tropism
 - novel promoters for restricted cellular expression
 - improved manufacturing
- Inducible promoters for viral delivery systems in the context of the gene therapies
- Chemogenetics
- Other transformative approaches that address neurological disorders with high unmet
- Medical needs
- Digital therapies
 - Behavioral and diagnostic apps for diseases indicated above

Exclusions/Out of Scope

- Targets without human genetic or pharmacological validation
- Symptom treatments are of lower priority
- Pain, Peripheral neuropathies, CNS oncology
- Amyloid Beta Therapies
- Tau and Alpha Synuclein therapies except for small molecules
- Anti-oxidants
- Addictions
- Stroke
- Spinal cord injury
- Traumatic brain injury
- Stress disorders (e.g. PTSD)
- Anxiety (high bar)
- Devices

Orion

Disease areas:

- Parkinson's Disease
- Amyotrophic lateral sclerosis
- Neuropathic pain
- Genetic disorders with neurological symptoms

*Interested in products, drug research/clinical research and R&D projects around focus areas.
Also looking for new target proteins/collaborations.*

Roche

Focus Areas:

- Alzheimer's
- Multiple sclerosis - MS
- Parkinson's
- Rare diseases
 - Duchenne Muscular Dystrophy – DMD
 - Spinal muscular atrophy - SMA
 - Neuromyelitis optica spectrum disorder - NMOSD

Areas/applications of interest with high preference to digital health solutions

- Integration and personalization of care
- Early diagnosis utilizing data capture and access, gamification, AI/ML
- Accelerating risk prediction, diagnostics, treatment decision support and response monitoring
- Identification of digital biomarkers
- For rare diseases specifically early diagnosis, early identification of disease onset

We are interested in research that will identify the areas of needs for improvement/segments along the care pathway, assessment and clinical validation of integrated care approach.

Sanofi Genzyme

Multiple Sclerosis

- Immunomodulation: Differentiated drug candidates targeting lymphocytes with novel mechanisms of action, with potential for high efficacy and improved safety
- Neuroinflammation: Drug candidates targeting CNS inflammatory milieu, including microglia and astrocytes
- Neuroprotection and remyelination: Drug candidates and novel mechanisms of action that prevent irreversible damage to neurons and glia, promote remyelination by oligodendrocytes and enhance regeneration
- Symptom Management: Drug candidates targeting MS-related cognitive and behavioral symptoms, preferably with clinical proof of concept

Genetically Defined Neurological Diseases

- Modulation of gene expression and gene replacement strategies and therapeutics targeting CNS genetic diseases, including Parkinson's Disease, Huntington's Disease, Friedreich's ataxia and Amyotrophic Lateral Sclerosis

Neurodegeneration

- Small molecules or biologics targeting alpha-synuclein or tau that reduce accumulation and spread of pathology
- Small molecules targeting CNS inflammatory milieu, including microglia and astrocytes
- Therapeutics and novel targets to normalize lysosomal or mitochondrial function

Translational Neuroscience and Technologies

- Biomarkers predictive of disease progression, treatment response, patient stratification
- PET ligands for misfolded proteins, neuroinflammation, therapeutic target engagement
- AAV capsids for intrathecal or systemic administration, widespread or region/cell specific transduction of brain cell types
- Methods of enhancing transit of therapeutics across the blood-brain-barrier
- Methods for assessing synaptic plasticity, synaptic loss, neuroprotection, remyelination *in vivo*

Read More About Areas of Interest for Partnering: <https://www.sanofi.com/en/science-and-innovation/partnering/creating-value-together>

Takeda

Therapeutic areas

- ADHD, with special focus on adult ADHD
- Sleep disorders, with special focus on Narcolepsy
- Epilepsy, with special focus on rare pediatric epilepsy, such as Dravet Syndrome and Lennox-Gastaut Syndrome

Solution areas

- Digital Health
- Early diagnosis
- Clinical decision-making support
- Treatment response monitoring
- Integrated care solutions
- Personalized treatment
- Digital biomarkers
- Technologies: Gamification, AR/VR, Machine learning / Artificial Intelligence, Wearables, sensors, IoT, etc
- Real World Evidence, Health Data, Clinical Biobanks, Registry Studies